Anika Therapeutics, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 11/30/25 | FY 12/31/24 | FY 12/31/23 | FY 11/30/23 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $112.8 | — | $119.9 | $120.8 | — |
| Operating income | -$11.1 | — | -$5.1 | $0.8 | — |
| Net income | -$10.9 | — | -$56.4 | -$82.7 | — |
| Cash Flow Statement | |||||
| Free cash flow | $4.4 | — | -$2.3 | -$7.2 | — |
| Share repurchases | $9.5 | — | $10.9 | $5.0 | — |
Shares outstanding 13.4M · Free float 76.2%
Annual filing data through FY ended December 31, 2025; float as of September 22, 2026.